These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32798155)

  • 1. Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis.
    Yaeger R; Paroder V; Bates DDB; Capanu M; Chou J; Tang L; Chatila W; Schultz N; Hersch J; Kelsen D
    Clin Colorectal Cancer; 2020 Dec; 19(4):e151-e156. PubMed ID: 32798155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
    Innocenti F; Sibley AB; Patil SA; Etheridge AS; Jiang C; Ou FS; Howell SD; Plummer SJ; Casey G; Bertagnolli MM; McLeod HL; Auman JT; Blanke CD; Furukawa Y; Venook AP; Kubo M; Lenz HJ; Parker JS; Ratain MJ; Owzar K
    Clin Cancer Res; 2021 Jan; 27(1):267-275. PubMed ID: 32958699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.
    Van Cutsem E; Joulain F; Hoff PM; Mitchell E; Ruff P; Lakomý R; Prausová J; Moiseyenko VM; van Hazel G; Cunningham D; Arnold D; Schmoll HJ; Ten Tije AJ; McKendrick J; Kröning H; Humblet Y; Grávalos C; Le-Guennec S; Andria M; Dochy E; Vishwanath RL; Macarulla T; Tabernero J
    Target Oncol; 2016 Jun; 11(3):383-400. PubMed ID: 26706237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
    Bendell JC; Bekaii-Saab TS; Cohn AL; Hurwitz HI; Kozloff M; Tezcan H; Roach N; Mun Y; Fish S; Flick ED; Dalal D; Grothey A
    Oncologist; 2012; 17(12):1486-95. PubMed ID: 23015662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological differentiation between sporadic and colitis-associated intestinal cancer in a nationwide study: A propensity-score-matched analysis.
    Uchino M; Ikeuchi H; Noguchi T; Okabayashi K; Futami K; Tanaka S; Ohge H; Watanabe K; Itabashi M; Okamoto K; Okita Y; Mizushima T; Mizuuchi Y; Yamada K; Shimada Y; Sato Y; Kimura H; Takahashi K; Hida K; Kinugasa Y; Okuda J; Daito K; Koyama F; Ueno H; Yamamoto T; Hanai T; Kono T; Kobayashi H; Ajioka Y; Sugihara K; Ishihara S;
    J Gastroenterol Hepatol; 2024 May; 39(5):893-901. PubMed ID: 38273469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
    Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
    Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients.
    Fernandes GDS; Braghiroli MI; Artioli M; Paterlini ACCR; Teixeira MC; Gumz BP; Girardi DDM; Braghiroli OFM; Costa FP; Hoff PM
    J Gastrointest Cancer; 2018 Dec; 49(4):470-475. PubMed ID: 28884286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
    Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Vascular Microenvironment of Colorectal Hepatic Metastasis and Chemotherapy Response.
    Okamoto H; Shiba S; Iino H; Sudoh M; Ichikawa D
    Anticancer Res; 2021 Sep; 41(9):4505-4513. PubMed ID: 34475076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry.
    Burge M; Semira C; Lee B; Lee M; Kosmider S; Wong R; Shapiro J; Ma B; Dean AP; Zimet AS; Steel SA; Lok SW; Torres J; Eastgate M; Wong HL; Gibbs P
    Clin Colorectal Cancer; 2018 Sep; 17(3):e593-e599. PubMed ID: 29958812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer.
    Dost Gunay FS; Kırmızı BA; Ensari A; İcli F; Akbulut H
    Clin Colorectal Cancer; 2019 Jun; 18(2):e244-e250. PubMed ID: 30670344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
    Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
    Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
    Kaneko M; Kotake M; Bando H; Yamada T; Takemura H; Minamoto T
    BMC Cancer; 2016 Dec; 16(1):945. PubMed ID: 27955637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer.
    Berlin J; Bendell JC; Hart LL; Firdaus I; Gore I; Hermann RC; Mulcahy MF; Zalupski MM; Mackey HM; Yauch RL; Graham RA; Bray GL; Low JA
    Clin Cancer Res; 2013 Jan; 19(1):258-67. PubMed ID: 23082002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience.
    Kim JH; Park SJ; Park MI; Moon W; Kim SE; Ku KH; Song SE; Kim JH
    Korean J Gastroenterol; 2014 Jan; 63(1):18-24. PubMed ID: 24463284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incomplete operative removal of colorectal liver metastases followed by chemotherapy decreases survival in comparison to chemotherapy alone.
    Popov IP; Milicevic M; Kecmanovic D; Tomasevic Z; Radosevic-Jelic Lj; Borojevic N; Micev MT; Kezic I
    J Exp Clin Cancer Res; 2006 Sep; 25(3):313-9. PubMed ID: 17167970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
    Del Rio M; Mollevi C; Bibeau F; Vie N; Selves J; Emile JF; Roger P; Gongora C; Robert J; Tubiana-Mathieu N; Ychou M; Martineau P
    Eur J Cancer; 2017 May; 76():68-75. PubMed ID: 28284171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database.
    Shinozaki E; Makiyama A; Kagawa Y; Satake H; Tanizawa Y; Cai Z; Piao Y
    PLoS One; 2021; 16(2):e0246160. PubMed ID: 33556095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.